Samsung Biologics Co.,Ltd. (KRX: 207940)

Samsung Biologics Co.,Ltd. Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	4,364,392	3,694,589	3,001,295	1,568,007	1,164,777	701,592
Other Revenue	-	-	-0	-	-	-0
Revenue	4,364,392	3,694,589	3,001,295	1,568,007	1,164,777	701,592
Revenue Growth (YoY)	21.69%	23.10%	91.41%	34.62%	66.02%	30.94%
Cost of Revenue	2,221,534	1,900,080	1,540,526	844,657	751,189	510,060
Gross Profit	2,142,857	1,794,509	1,460,769	723,350	413,588	191,532
Selling, General & Admin	630,711	535,421	380,456	169,630	110,009	88,878
Research & Development	103,174	81,588	45,884	954.22	-	-
Other Operating Expenses	10,335	10,339	7,448	1,804	1,789	1,660
Operating Expenses	798,501	680,829	477,142	186,040	120,802	99,789
Operating Income	1,344,356	1,113,680	983,627	537,309	292,787	91,742
Interest Expense	-45,458	-81,596	-64,064	-14,707	-16,086	-25,615
Interest & Investment Income	75,756	95,650	53,293	9,656	13,140	17,246
Earnings From Equity Investments	30.95	-499.42	27,260	13,853	-17,768	72,940
Currency Exchange Gain (Loss)	-28,965	-11,186	-63,503	17,874	-3,196	-4,374
Other Non Operating Income (Expenses)	9,099	2,652	2,347	4,494	3.96	4,254
EBT Excluding Unusual Items	1,354,820	1,118,701	938,960	568,479	268,882	156,194
Gain (Loss) on Sale of Investments	217.82	5,152	72,653	269.12	303.96	407.22
Gain (Loss) on Sale of Assets	-3,289	-3,866	-2,588	-7,466	-1,841	-806.21
Asset Writedown	-	-	-	-	-1,352	-359.6
Pretax Income	1,351,748	1,119,987	1,009,025	561,283	265,992	155,435
Income Tax Expense	299,243	262,296	210,968	167,693	25,017	-47,469
Earnings From Continuing Operations	1,052,506	857,691	798,056	393,589	240,975	202,904
Net Income	1,052,506	857,691	798,056	393,589	240,975	202,904
Net Income to Common	1,052,506	857,691	798,056	393,589	240,975	202,904
Net Income Growth	12.34%	7.47%	102.76%	63.33%	18.76%	-9.46%
Shares Outstanding (Basic)	71	71	70	66	66	66
Shares Outstanding (Diluted)	71	71	70	66	66	66
Shares Change (YoY)	-0.01%	1.95%	5.51%	-	-	-
EPS (Basic)	14787.79	12050.63	11442.19	5948.61	3642.03	3066.64
EPS (Diluted)	14787.79	12050.63	11432.00	5948.61	3642.03	3066.64
EPS Growth	12.34%	5.41%	92.18%	63.33%	18.76%	-9.46%
Free Cash Flow	1,098,950	671,158	-3,792	48,343	62,425	-182,684
Free Cash Flow Per Share	15440.33	9429.82	-54.32	730.64	943.48	-2761.04
Gross Margin	49.10%	48.57%	48.67%	46.13%	35.51%	27.30%
Operating Margin	30.80%	30.14%	32.77%	34.27%	25.14%	13.08%
Profit Margin	24.12%	23.21%	26.59%	25.10%	20.69%	28.92%
Free Cash Flow Margin	25.18%	18.17%	-0.13%	3.08%	5.36%	-26.04%
EBITDA	1,934,585	1,603,462	1,291,892	699,098	436,475	224,627
EBITDA Margin	44.33%	43.40%	43.04%	44.59%	37.47%	32.02%
D&A For EBITDA	590,229	489,782	308,264	161,789	143,688	132,885
EBIT	1,344,356	1,113,680	983,627	537,309	292,787	91,742
EBIT Margin	30.80%	30.14%	32.77%	34.27%	25.14%	13.08%
Effective Tax Rate	22.14%	23.42%	20.91%	29.88%	9.41%	-
Advertising Expenses	-	11,916	8,829	5,349	4,396	6,481

Source: S&P Capital IQ. Standard template. Financial Sources.